SARS-CoV-2感染与产科并发症所致严重孕产妇疾病和死亡的相关性
该回顾性队列研究纳入2020年3月1日至2020年12月31日在美国17家医院分娩的14104例妊娠及产后患者,其中2352例SARS-CoV-2阳性,11752例无阳性检测结果。主要结局为孕产妇死亡或与妊娠期高血压疾病、产后出血或非SARS-CoV-2感染相关的严重疾病的复合结局。SARS-CoV-2感染与主要结局显著相关(13.4% vs 9.2%;差值4.2% [95%CI 2.8%-5.6%];aRR 1.41 [95%CI 1.23-1.61]),5例孕产妇死亡均在SARS-CoV-2组。中重度COVID-19与主要结局(aRR 2.06)和剖宫产(aRR 1.17)显著相关,轻症或无症状感染与主要结局及剖宫产均无显著相关。
要点
- SARS-CoV-2感染孕产妇主要复合结局(孕产妇死亡或妊娠期高血压疾病、产后出血、非SARS-CoV-2感染相关严重疾病)发生率13.4% vs 无阳性检测结果者9.2%,aRR 1.41(95%CI 1.23-1.61)。
- 中重度COVID-19(n=586)主要结局发生率26.1% vs 9.2%,差值16.9%(95%CI 13.3%-20.4%),aRR 2.06(95%CI 1.73-2.46)。
- 轻症或无症状感染(n=1766)主要结局发生率9.2% vs 9.2%,差值0%(95%CI -1.4%至1.4%),aRR 1.11(95%CI 0.94-1.32),无显著相关。
- SARS-CoV-2感染与剖宫产无显著相关(34.7% vs 32.4%;aRR 1.05 [95%CI 0.99-1.11]);中重度COVID-19与剖宫产显著相关(45.4% vs 32.4%;aRR 1.17 [95%CI 1.07-1.28])。
- 全部5例孕产妇死亡均发生在SARS-CoV-2感染组。
适用人群与场景
- 2020年3月1日至2020年12月31日在美国17家医院分娩的妊娠及产后患者,最终随访至2021年2月11日。
- 所有SARS-CoV-2阳性患者均纳入,并与同期随机选取日期分娩的无SARS-CoV-2阳性检测结果者比较。
诊断标准与关键阈值
- SARS-CoV-2感染基于核酸或抗原检测阳性结果。
- 按疾病严重程度分层:中重度COVID-19(n=586)与轻症或无症状感染(n=1766)。
研究设计与关键结果
- 回顾性队列研究,纳入14104例妊娠及产后患者(平均年龄29.7岁),其中2352例SARS-CoV-2感染,11752例无阳性检测结果。
- 主要结局为孕产妇死亡或与妊娠期高血压疾病、产后出血或非SARS-CoV-2感染相关的严重疾病的复合结局。
- SARS-CoV-2感染与主要结局显著相关:13.4% vs 9.2%;差值4.2%(95%CI 2.8%-5.6%);aRR 1.41(95%CI 1.23-1.61)。
- 全部5例孕产妇死亡均发生在SARS-CoV-2感染组。
- SARS-CoV-2感染与剖宫产无显著相关:34.7% vs 32.4%;aRR 1.05(95%CI 0.99-1.11)。
- 中重度COVID-19(n=586)与主要结局显著相关:26.1% vs 9.2%;差值16.9%(95%CI 13.3%-20.4%);aRR 2.06(95%CI 1.73-2.46)。
- 中重度COVID-19与剖宫产显著相关:45.4% vs 32.4%;差值12.8%(95%CI 8.7%-16.8%);aRR 1.17(95%CI 1.07-1.28)。
- 轻症或无症状感染(n=1766)与主要结局无显著相关:9.2% vs 9.2%;差值0%(95%CI -1.4%至1.4%);aRR 1.11(95%CI 0.94-1.32);与剖宫产无显著相关:31.2% vs 32.4%;差值-1.4%(95%CI -3.6%至0.8%);aRR 1.00(95%CI 0.93-1.07)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在美国17家医院的妊娠及产后人群中,SARS-CoV-2感染与产科并发症所致孕产妇死亡或严重疾病的复合结局风险增加相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: It remains unknown whether SARS-CoV-2 infection specifically increases the risk of serious obstetric morbidity.
OBJECTIVE: To evaluate the association of SARS-CoV-2 infection with serious maternal morbidity or mortality from common obstetric complications.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of 14 104 pregnant and postpartum patients delivered between March 1, 2020, and December 31, 2020 (with final follow-up to February 11, 2021), at 17 US hospitals participating in the Eunice Kennedy Shriver National Institute of Child Health and Human Development's Gestational Research Assessments of COVID-19 (GRAVID) Study. All patients with SARS-CoV-2 were included and compared with those without a positive SARS-CoV-2 test result who delivered on randomly selected dates over the same period.
EXPOSURES: SARS-CoV-2 infection was based on a positive nucleic acid or antigen test result. Secondary analyses further stratified those with SARS-CoV-2 infection by disease severity.
MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of maternal death or serious morbidity related to hypertensive disorders of pregnancy, postpartum hemorrhage, or infection other than SARS-CoV-2. The main secondary outcome was cesarean birth.
RESULTS: Of the 14 104 included patients (mean age, 29.7 years), 2352 patients had SARS-CoV-2 infection and 11 752 did not have a positive SARS-CoV-2 test result. Compared with those without a positive SARS-CoV-2 test result, SARS-CoV-2 infection was significantly associated with the primary outcome (13.4% vs 9.2%; difference, 4.2% [95% CI, 2.8%-5.6%]; adjusted relative risk [aRR], 1.41 [95% CI, 1.23-1.61]). All 5 maternal deaths were in the SARS-CoV-2 group. SARS-CoV-2 infection was not significantly associated with cesarean birth (34.7% vs 32.4%; aRR, 1.05 [95% CI, 0.99-1.11]). Compared with those without a positive SARS-CoV-2 test result, moderate or higher COVID-19 severity (n = 586) was significantly associated with the primary outcome (26.1% vs 9.2%; difference, 16.9% [95% CI, 13.3%-20.4%]; aRR, 2.06 [95% CI, 1.73-2.46]) and the major secondary outcome of cesarean birth (45.4% vs 32.4%; difference, 12.8% [95% CI, 8.7%-16.8%]; aRR, 1.17 [95% CI, 1.07-1.28]), but mild or asymptomatic infection (n = 1766) was not significantly associated with the primary outcome (9.2% vs 9.2%; difference, 0% [95% CI, -1.4% to 1.4%]; aRR, 1.11 [95% CI, 0.94-1.32]) or cesarean birth (31.2% vs 32.4%; difference, -1.4% [95% CI, -3.6% to 0.8%]; aRR, 1.00 [95% CI, 0.93-1.07]).
CONCLUSIONS AND RELEVANCE: Among pregnant and postpartum individuals at 17 US hospitals, SARS-CoV-2 infection was associated with an increased risk for a composite outcome of maternal mortality or serious morbidity from obstetric complications.
参考来源
- Metz TD, Clifton RG, Hughes BL, et al. Association of SARS-CoV-2 Infection With Serious Maternal Morbidity and Mortality From Obstetric Complications. JAMA. 2022. PMID: 35129581. doi:10.1001/jama.2022.1190
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。